Terbinafine is currently the most interesting of a new class of synthetic antimycotic agents, the allylamines.8 It may be taken orally and is fungicidal, inhibiting the fungal enzyme squalene epoxidase, which is important in the biosynthesis of ergosterol, an essential constituent of the fungal cell membrane. Inhibition of squalene epoxidase leads to a decrease in membrane ergosterol and accumulation of intracellular squalene, both of which are thought to contribute to the fungicidal action of terbinafine.9 This action is different from that of azole antifungals, which also inhibit ergosterol production in fungi, but by inhibiting lanosterol demethylase, an enzyme dependent on cytochrome P-450.'°Other cytochrome P-450 linked enzymes are also inhibited by azole derivatives, though less with triazoles such as itraconazole. Possibly, these differences may explain the different side effects of these three groups of drugs."
Terbinafine is effective in the treatment of dermatophyte infections of skin and nails,2-'4 and its use BMJ VOLUME 304 for these conditions is now licensed in the United Kingdom in both hospital and general practice. Its effectiveness and safety in nail dermatophytosis was confirmed when given for up to 12 months for toenail infections and up to six months for fingernail infections.14 15 The speed with which mycological cure was achieved and the known fungicidal action of the drug suggested that shorter courses of treatment might be successful for treating fungal nail disease. We report a multicentre study of the effectiveness of terbinafine given for three months for treating nail dermatophytosis.
Patients and methods
Patients with clinical subungual dermatophytosis were randomised (with random tables of Fisher and Yates) in a double blind, placebo controlled parallel group comparison of terbinafine 250 mg nightly, given for 12 weeks and placebo. Sample size was calculated using a power of 90%, with a equal to 5%; a randomisation of 3:1 active to placebo treatment was chosen for ethical reasons, and this, assuming a mycological cure in 55% of patients taking the drug and in 20% taking placebo, required 81 subjects. To allow for 20% drop out it was intended that 100 patients would be recruited in eight centres in the United Kingdom.
Successive patients attending the dermatology outpatient departments of these centres who showed clinical evidence of nail infection were screened for inclusion in the study after written consent had been obtained. Patients with pre-existing renal, hepatic, or gastrointestinal disease and psoriasis or yeast infection of the nails and women who were pregnant or using inadequate contraception were excluded from the study. Mycological investigations were performed centrally in Leeds and comprised direct microscopy of nail clippings in 20% w/v potassium hydroxide, followed by culture on Sabouraud's glucose agar with added chloramphenicol (0 05% w/v) and actidione (0 5% w/v) at 27°C for up to three weeks. Only patients with a dermatophyte infection, confirmed by positive microscopy and culture before the start of treatment, were eligible for inclusion in the trial. Patients with either fingernail or toenail infection were included and received identical treatment. After treatment, patients were followed up for a further 36 weeks, when a final evaluation of efficacy was made. Patients who received placebo and failed to show improvement were offered active treatment after 16 or 24 weeks, depending on the views of the local hospital ethical committee. If they received treatment they were classified as placebo treatment failures.
Before starting treatment a full clinical examination and full biochemical and haematological investigations were performed and nail samples were examined mycologically. The number and site of infected nails were recorded, and the worst affected nail was chosen for specific measurement and observation. The proximal extent of nail involvement was marked by cutting a groove on the nail, and the distance from the proximal nail fold was measured. This measurement was repeated at each visit, allowing the appearance of unaffected nail to be recorded, as described by Zaias and Drackman. 16 Patients were seen at monthly intervals throughout the treatment period. At each visit the mycological, biochemical, and haematological investigations were repeated; compliance and the occurrence of side effects were ascertained, and the target nail was examined clinically. Patients who experienced appreciable side effects or whose laboratory test results became abnormal were withdrawn at the discretion of the investigator.
The mycological cure rates at the end of the treatment period and of follow up were compared by the X2 test. Mycological cure was defined as negative findings on microscopy and culture. The trial end points were thus 12 weeks (end of treatment) and 48 weeks (end of follow up).
Results
One hundred and twelve patients were enrolled into the study, 99 (70 taking terbinafine, 29 placebo) with toenail infection and 13 (eight taking terbinafine and five placebo) with fingernail infection. Seventeen patients had toe and fingernail involvement and were included in the toenail group because these infections are more difficult to treat. There were eight delayed exclusions because of negative mycological findings at baseline (five patients with negative cultures; three with negative results on microscopy), and 19 other patients failed to complete the study or were excluded from the analysis owing to significant violations of the study protocol (table I) Discussion Dermatophyte nail infection is not a serious problem in terms of overall morbidity and mortality, but it is a source of inconvenience, pain, and discomfort to individual patients, many of whom also find it cosmetically unacceptable. The infection contributes to and perpetuates the reservoir of dermatophyte fungi responsible for the spread of infection among those who use communal bathing facilities such as swimming pools and showers. Until now no really effective and safe treatment for dermatophytosis of nails has existed, though results obtained with long term terbinafine treatment are encouraging and suggest that this drug may be a major advance.'5
Our study reinforces that view and indicates that long term treatment is not necessary for even the most severe and chronic nail infections. The cure rates achieved with three months' treatment were comparable to those found with 12 months' treatment-thus there seems to be no advantage in prolonging treatment beyond three months. Delayed clinical cure was noted in an earlier study'7 and was seen again here. The clinical cure rates are almost certainly still underestimated because ofthe slow rate ofgrowth oftoenails and can be expected to increase further with time.
The drug was well tolerated, and shorter duration treatment is as safe as a course of six to 12 months. In this study the profile of adverse events was similar with terbinafine and placebo and, as in earlier studies, indicated that mild gastrointestinal upset is the major side effect. Encouragingly, there were no important changes in laboratory variables. Though unusual side effects may appear once terbinafine is widely used, the existing pharmacological and clinical evidence suggests that this is unlikely.
The patients in whom terbinafine treatment failed comprised two groups. The first included those who never achieved a mycological cure at any stage in the study, in whom the failures may be true failures, though late cure may still occur. The second included those who achieved a mycological cure but whose infection subsequently relapsed. With a short treatment course these relapses are probably true relapses rather than reinfections.
Terbinafine, the first orally active drug of the allylamine class of antifungal agents, is an effective and safe treatment for dermatophyte onychomycosis, and short term treatment is as effective as longer courses. This is a considerable advance in the management of dermatophyte nail infections. Of other available drugs, a comparison with itraconazole would be valuable, but given that itraconazole is a fungistatic drug against dermatophytes, terbinafine is likely to be more effective. Griseofulvin has remained the standard treatment for dermatophytosis but is relatively ineffective. Its main benefit is that it is cheap. However, three months of terbinafine treatment (£137.40) costs little more than 18 months of griseofulvin treatment (5295.00) and cures about twice as many patients. Numbers of newly presenting patients with non-insulin dependent diabetes (n=100) categorised according to duration of previously recognised or unrecognised symptoms
